Aptus Pharma Ltd (APPL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Aptus Pharma Ltd on NSE and BSE, with an AI summary of each filing.
Receipt of In-Principle Approval for Preferential Issue
Others (Uncategorized) · 31 Oct 2026, 1:01 am
Aptus Pharma Receives In-Principle BSE Approval for Preferential Issue Aptus Pharma Ltd. received in-principle approval from BSE Ltd. on 30th Oct'26 under Regulation 28(1) of SEBI LODR Regulations for a proposed preferential issue. The approval covers the issuance of 15,99,270 equity shares (face value of Rs. 10 each) at a minimum price of Rs. 280 per share to promoters and non-promoters, aggregating to at least Rs. 44.78 cr. The issue was previously approved by shareholders at the AGM on 14th Sep'26. Final listing remains subject to regulatory compliance and post-allotment filings.
Transcript for Earning Call for the Quarter and Half Year ended on September 30, 2026
Transcript · 30 Oct 2026, 1:00 am
Audio recording of the Earnings Call dated October 26, 2026
Audio / Video · 27 Oct 2026, 1:12 am
Aptus Pharma Uploads Audio Recording for H1 FY27 Earnings Call Aptus Pharma Limited informed BSE that the audio recording of its earnings conference call held on 26th Oct'26 has been uploaded to its official website. The call discussed financial and operational performance for the half-year ended 30th Sep'26, pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Intimation of Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Investor Presentation · 23 Oct 2026, 11:01 pm
Aptus Pharma Delivers Strong H1 FY27 Growth with Expansion Roadmap Aptus Pharma reported robust financial results for the half year ended 30th Sep'26, with revenue from operations surging nearly twofold YoY to ₹48.92 crore, compared to ₹14.38 crore in H1 FY26. EBITDA stood at ₹7.68 crore, while net profit reached ₹5.08 crore against ₹1.75 crore in the previous year period. Acute therapy contributed ~44% of sales, followed by chronic (~20%) and wellness/OTC (~20%). Strategically, the company plans 46% geographic coverage by Mar'27, 20% in-house manufacturing by Mar'28, and a pan-India footprint by Mar'29.
Intimation of Earnings Call for the quarter and half year ended September 30, 2026
Intimation · 26 Oct 2026, 5:00 pm
Aptus Pharma Schedules Q2 FY27 Earnings Conference Call for 26th Oct'26 Aptus Pharma Limited has scheduled an audio earnings conference call on 26th Oct'26 at 5:00 PM IST to discuss its financial performance for Q2 and H1 FY27, ended 30th Sep'26. Key leadership, including Managing Director Tejash Hathi, CEO Ghanshyam Pansuriya, CFO Kapil Chandarana, and VP Domestic Nirav Pandya, will present updates on recent business developments, growth strategies, and the forward business outlook. Registered access is available via Diamond Pass, with general dial-in access provided under participant PIN 1954595#.
Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company ....
Financial Result · 21 Oct 2026, 12:59 am
Aptus Pharma Reports Strong H1 Performance with Revenue Doubling to INR 48.92 Crore Aptus Pharma approved unaudited results for the half year ended 30th Sep'26, reporting revenue from operations of INR 48.92 crore (up 240% YoY from INR 14.38 crore), EBITDA of INR 7.68 crore, and PAT surging to INR 5.08 crore versus INR 1.75 crore in the prior period. EPS stood at INR 2.96. The company approved a preferential equity issue of 16.03 lakh shares at INR 280 each, aggregating INR 44.88 crore, awaiting BSE approval. Management targets 46% geographic coverage across India by Mar'27.
Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company ....
Outcome · 21 Oct 2026, 12:30 am
Aptus Pharma Reports Strong H1 Performance and Approves Preferential Equity Issue For the half year ended 30th Sep'26, Aptus Pharma reported standalone revenue from operations of INR 48.92 cr, up 240% YoY from INR 14.38 cr. Profit after tax rose 191% YoY to INR 5.08 cr versus INR 1.75 cr, with half-year EPS at INR 2.96. Shareholders approved a preferential issue of 16.03 lakh equity shares at INR 280 per share (including INR 270 premium), raising INR 44.88 cr, pending BSE in-principle approval. The company targets 46% pan-India geographic coverage by Mar'27.
Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2026 ,inter alia, to consider and approve Board Meeting Intimation for consideration ....
Intimation · 20 Oct 2026, 5:30 am
Aptus Pharma Schedules Board Meeting on 20th Oct'26 for Half-Year Results Aptus Pharma Limited has scheduled a Board of Directors meeting on 20th Oct'26 to consider, approve, and take on record the company's Unaudited Financial Results and Limited Review Report for the half-year ended 30th Sep'26. Additionally, pursuant to SEBI insider trading regulations, the trading window for dealing in the company's securities has been closed effective 1st Oct'26 and will remain closed until 48 hours after the declaration of the financial results.
Intimation of Investor Meeting/Interaction
Intimation · 17 Sept 2026, 8:06 pm
Aptus Pharma Scheduled for Arihant Capital Virtual Investor Conference Aptus Pharma Limited announced under Regulation 30 of Listing Regulations that its management will participate in a virtual group investor interaction at the "Arihant Capital: Bharat Connect Conference – Rising Stars." The meeting is scheduled for Friday, 25th Sep'26, from 3:00 pm to 4:00 pm. Discussions during the session will strictly pertain to publicly available information, subject to changes due to exigencies.
Scrutinizer''s Report on remote E-Voting
Annual General Meeting · 15 Sept 2026, 1:55 am
Aptus Pharma Shareholders Approve Preferential Issue and Key AGM Resolutions Aptus Pharma Limited announced the voting results of its 16th AGM held on 14th Sep'26. Shareholders unanimously approved all three proposed resolutions with 100% votes in favor across 13.94m votes polled. Key approvals include the adoption of FY26 audited financial statements, the re-appointment of Director Chetan Shantilal Lalseta retiring by rotation, and a special resolution approving the preferential allotment of equity shares. Remote e-voting concluded on 13th Sep'26, scrutinized by Practising Company Secretary Nalin Ganatra.
Summary of proceedings of the 16th Annual General Meeting of the Company held on 14th September, 2026
Annual General Meeting · 15 Sept 2026, 1:09 am
Intimation of Investor meeting / interaction
Intimation · 12 Sept 2026, 7:03 pm
Aptus Pharma Schedules Group Investor Meeting on 18th Sep'26 Aptus Pharma Limited informed exchanges that company management will host a group interaction with investors and analysts on 18th Sep'26 from 4:00 PM to 6:00 PM in Mumbai. The discussions will center exclusively on publicly available information in compliance with SEBI LODR regulations.
CORRIGENDUM / ADDENDUM TO NOTICE OF ANNUAL GENERAL MEETING AND E-VOTING
Annual General Meeting · 08 Sept 2026, 1:43 am
Aptus Pharma Limited - Press release regarding - Aptus Pharma Limited charts next growth phase with focus on manufacturing, pan-India expansion and global markets
Press Release · 24 Aug 2026, 7:04 pm
Aptus Pharma Plans ₹44.88 Cr Preferential Issue for Strategic Expansion Aptus Pharma has approved a proposal to raise ₹44.88 crore via a preferential issue to fund its next growth phase. The plan, announced on 24th Aug'26, allocates ₹25 crore for capex (manufacturing plant, storage), ₹10 crore for working capital, and ₹9.88 crore for corporate purposes. The strategy pivots from marketing-led to developing in-house manufacturing, aiming to fulfill 20% of product needs internally. Aptus also plans a pan-India sales expansion and entry into international markets like Africa, the Middle East, and Latin America.
Intimation of investor presentation under regulation 30 of SEBI (LODR) Regulations, 2015
Investor Presentation · 22 Aug 2026, 1:17 am
Aptus Pharma FY26 Results: Strong Revenue and PAT Growth Aptus Pharma reported strong FY26 results, with revenue doubling to ₹4,670.81 lakh (+89.6% YoY) and PAT growing to ₹461.99 lakh (+49.1% YoY). EBITDA stood at ₹750.32 lakh, up 57.7% YoY. This performance was driven by an asset-light model and expansion across Rx, OTC, and global verticals. The company expanded its portfolio to over 250 formulations and its distribution network to 25,000+ retailers. Strategically, Aptus aims for pan-India presence by Mar'29 and 20% own-manufacturing by Mar'28 to support global expansion plans.
SUB: Submission of Annual Report for the FY 2025-26 comprising of the Notice of Annual General Meeting, Directors Report, Independent Auditors Report and Audited Financial Statements
Others (Uncategorized) · 22 Aug 2026, 1:06 am
Notice is hereby given that the Annual General Meeting of the Company will be held on Monday 14th September, 2026, Through Video Conferencing (VC)/ Other Audio visual means.
Annual General Meeting · 22 Aug 2026, 12:56 am
Outcome of Board Meeting dated 17.08.2026
Outcome · 17 Aug 2026, 11:37 pm
Aptus Pharma Board Approves Preferential Allotment to Raise Rs. 44.88 Crore Aptus Pharma's board, in its meeting on 17 Aug'26, approved a preferential issue of 16,02,870 equity shares at a price of Rs. 280 per share, aggregating to Rs. 44.88 crore. The shares, with a face value of Rs. 10 each, will be allotted to 190 investors. The relevant date for the pricing was 14 Aug'26. The company also approved convening its 16th Annual General Meeting on 14 Sep'26 to seek shareholder approval for the preferential issue.
Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 ,inter alia, to consider and approve Prior Intimation of Board Meeting ....
Intimation · 12 Aug 2026, 11:25 pm
Aptus Pharma Board to Consider Preferential Share Issue Pricing Aptus Pharma's Board of Directors will meet on 17 Aug'26 to determine the issue price for a preferential allotment of 16,10,100 equity shares. The pricing will be based on a valuation report with a relevant date of 14 Aug'26. The board will also consider related compliance certificates and convene the 16th AGM for 14 Sep'26. The trading window is closed for designated persons from 12 Aug'26 until 48 hours after the meeting's outcome is announced.
Please find attached Clarification letter in respect of Outcome of Board meeting held on 08.08.2026 and submitted on 08.08.2026 for approval of Preferential issue of Shares
Outcome · 10 Aug 2026, 8:09 pm
Aptus Pharma Corrects Typographical Errors in Board Meeting Outcome Aptus Pharma issued a clarification on 10th Aug'26 regarding its Board Meeting outcome from 08th Aug'26. The company corrected two typographical errors: the meeting venue was the Head Office, not the Registered Office, and an annexure was mislabeled. Aptus Pharma confirmed these errors were purely clerical and had no substantive impact on the decisions or resolutions passed during the meeting, which included the approval for a preferential issue of shares. All outcomes remain unchanged.
please find attached outcome of board meeting dated 08.08.2026 for approval of preferential issue of shares
Outcome · 08 Aug 2026, 10:57 pm
Aptus Pharma Approves Preferential Issue of 1.61 Million Equity Shares Aptus Pharma's board, on 08 Aug'26, approved a preferential issue of 1,610,100 equity shares with a face value of ₹10 each. The price will be determined based on a valuation report, with 14 Aug'26 set as the relevant date for pricing. The issue is subject to shareholder approval at the Annual General Meeting scheduled for 14 Sep'26. A total of 192 investors, including both promoter and non-promoter groups, are proposed allottees. This action will dilute existing shareholding.
Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting to ....
Intimation · 06 Aug 2026, 12:12 am
Aptus Pharma Board Meeting on 8th Aug'26 to Consider Fundraising Aptus Pharma (APPL) has scheduled a Board of Directors meeting for 8th Aug'26 to consider and evaluate a proposal for raising funds. The potential fundraising would be executed via a preferential allotment of equity shares or other eligible securities, subject to shareholder and regulatory approvals. In connection with this meeting, the trading window for designated persons and their relatives is closed from 5th Aug'26 and will reopen 48 hours after the meeting's outcome is publicly disclosed to the stock exchange.
Intimation Regarding Credit Rating assigned by CARE Ratings under Reluation 30 of SEBI (LODR) Regulations, 2015.
Others (Uncategorized) · 27 Jun 2026, 7:10 pm
Aptus Pharma Assigned 'CARE BB; Stable' Issuer Rating by CARE Ratings CARE Ratings assigned Aptus Pharma a 'CARE BB; Stable' issuer rating on 26-Jun'26. The rating is constrained by a modest scale, working capital intensity, and geographical concentration. However, it benefits from a comfortable capital structure post-IPO, healthy profitability, and experienced promoters. For FY26, total operating income grew ~90% YoY to ₹46.57 crore. Overall gearing improved to 0.31x from 1.49x in FY25 following a ₹13.02 crore IPO. Liquidity remains stretched with an elongated operating cycle and negative CFO of ₹5.61 crore.
Outcome of Board Meeting held on 12th June, 2026
Outcome · 12 Jun 2026, 11:16 pm
Aptus Pharma Board Approves ₹51 Crore Fundraise for Business Expansion Aptus Pharma's Board approved a proposal on 12-Jun'26 to raise up to ₹51 crore for business expansion, subject to shareholder and regulatory approvals. The fundraising plan includes a preferential allotment of securities up to ₹35 crore, debt finance/borrowings of up to ₹10 crore, and internal accruals of ₹6 crore. Specific details like issue price and investor identity have not been finalized and will be determined at a subsequent Board meeting. The Managing Director has been authorized to identify potential investors.
Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/06/2026 ,inter alia, to consider and approve Intimation of Board Meeting to ....
Intimation · 10 Jun 2026, 12:03 am
Aptus Pharma Board to Consider Fundraising via Equity and Debt Aptus Pharma's Board of Directors will meet on 12 Jun'26 to evaluate and approve a proposal for raising funds. The agenda includes issuing equity shares or other securities through a preferential allotment and securing borrowings from banks or financial institutions. The proposal is currently at an exploratory stage, with specific details like the amount and issue price to be finalized later. The trading window for designated persons is closed from 09 Jun'26 until 48 hours after the meeting's outcome is announced.